Prellis: Prellis Biologics Secures $14.5M for Bioprinted Lymph Node
Prellis Biologics secured a $14.5 million series B round lead by Celesta Capital with existing shareholders Khosla Ventures. Prellis has an Externalized Immune System (EXIS) platform which allows... View the entire article via our website.
Read full article »
Prellis is a California-based biotechnology firm that develops and supplies 3D printed lymph nodes drug discovery and development systems for the healthcare industry.
Read more